BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 29028121)

  • 1. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S; Nguyen R; Opie JM; Andrews MC
    Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA; Elshimy N; Muinonen-Martin A; Marples M; Mathew B; Mitra A
    Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 inhibitor induced alopecia areata.
    Guidry J; Brown M; Medina T
    Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
    JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
    Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR
    Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P
    Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
    [No Abstract]   [Full Text] [Related]  

  • 8. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
    Amini-Adle M; Balme B; Dalle S
    Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
    [No Abstract]   [Full Text] [Related]  

  • 9. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
    Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
    J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
    J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R; Metelitsa AI; Naert KA
    Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
    Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
    [No Abstract]   [Full Text] [Related]  

  • 13. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S; Ieremia E; Matin RN
    Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
    [No Abstract]   [Full Text] [Related]  

  • 14. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.
    Hwang SJ; Carlos G; Chou S; Wakade D; Carlino MS; Fernandez-Penas P
    Melanoma Res; 2016 Aug; 26(4):413-6. PubMed ID: 27031539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
    Mochel MC; Ming ME; Imadojemu S; Gangadhar TC; Schuchter LM; Elenitsas R; Payne AS; Chu EY
    J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Two cases of granuloma annulare under anti-PD1 therapy].
    Charollais R; Aubin F; Roche-Kubler B; Puzenat E
    Ann Dermatol Venereol; 2018 Feb; 145(2):116-119. PubMed ID: 29221649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
    Hofmann L; Forschner A; Loquai C; Goldinger SM; Zimmer L; Ugurel S; Schmidgen MI; Gutzmer R; Utikal JS; Göppner D; Hassel JC; Meier F; Tietze JK; Thomas I; Weishaupt C; Leverkus M; Wahl R; Dietrich U; Garbe C; Kirchberger MC; Eigentler T; Berking C; Gesierich A; Krackhardt AM; Schadendorf D; Schuler G; Dummer R; Heinzerling LM
    Eur J Cancer; 2016 Jun; 60():190-209. PubMed ID: 27085692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
    Fiset PO; Shapera S; Butler MO; Tsao MS
    Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
    [No Abstract]   [Full Text] [Related]  

  • 19. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uveal Effusion After Immune Checkpoint Inhibitor Therapy.
    Thomas M; Armenti ST; Ayres MB; Demirci H
    JAMA Ophthalmol; 2018 May; 136(5):553-556. PubMed ID: 29677240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.